221 related articles for article (PubMed ID: 37140166)
21.
Schmutz I; Mensenkamp AR; Takai KK; Haadsma M; Spruijt L; de Voer RM; Choo SS; Lorbeer FK; van Grinsven EJ; Hockemeyer D; Jongmans MC; de Lange T
Elife; 2020 Dec; 9():. PubMed ID: 33258446
[TBL] [Abstract][Full Text] [Related]
22. Cancer spectrum and outcomes in the Mendelian short telomere syndromes.
Schratz KE; Haley L; Danoff SK; Blackford AL; DeZern AE; Gocke CD; Duffield AS; Armanios M
Blood; 2020 May; 135(22):1946-1956. PubMed ID: 32076714
[TBL] [Abstract][Full Text] [Related]
23. Telomere Attrition and Clonal Hematopoiesis of Indeterminate Potential in Cardiovascular Disease.
Huang YC; Wang CY
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576030
[TBL] [Abstract][Full Text] [Related]
24. A new POT1 germline mutation-expanding the spectrum of POT1-associated cancers.
Wilson TL; Hattangady N; Lerario AM; Williams C; Koeppe E; Quinonez S; Osborne J; Cha KB; Else T
Fam Cancer; 2017 Oct; 16(4):561-566. PubMed ID: 28389767
[TBL] [Abstract][Full Text] [Related]
25. Replication stress conferred by POT1 dysfunction promotes telomere relocalization to the nuclear pore.
Pinzaru AM; Kareh M; Lamm N; Lazzerini-Denchi E; Cesare AJ; Sfeir A
Genes Dev; 2020 Dec; 34(23-24):1619-1636. PubMed ID: 33122293
[TBL] [Abstract][Full Text] [Related]
26. Investigation of conformational dynamics of Tyr89Cys mutation in protection of telomeres 1 gene associated with familial melanoma.
Amir M; Ahamad S; Mohammad T; Jairajpuri DS; Hasan GM; Dohare R; Islam A; Ahmad F; Hassan MI
J Biomol Struct Dyn; 2021 Jan; 39(1):35-44. PubMed ID: 31847782
[TBL] [Abstract][Full Text] [Related]
27. POT1 loss-of-function variants predispose to familial melanoma.
Robles-Espinoza CD; Harland M; Ramsay AJ; Aoude LG; Quesada V; Ding Z; Pooley KA; Pritchard AL; Tiffen JC; Petljak M; Palmer JM; Symmons J; Johansson P; Stark MS; Gartside MG; Snowden H; Montgomery GW; Martin NG; Liu JZ; Choi J; Makowski M; Brown KM; Dunning AM; Keane TM; López-Otín C; Gruis NA; Hayward NK; Bishop DT; Newton-Bishop JA; Adams DJ
Nat Genet; 2014 May; 46(5):478-481. PubMed ID: 24686849
[TBL] [Abstract][Full Text] [Related]
28. Dissecting Fission Yeast Shelterin Interactions via MICro-MS Links Disruption of Shelterin Bridge to Tumorigenesis.
Liu J; Yu C; Hu X; Kim JK; Bierma JC; Jun HI; Rychnovsky SD; Huang L; Qiao F
Cell Rep; 2015 Sep; 12(12):2169-80. PubMed ID: 26365187
[TBL] [Abstract][Full Text] [Related]
29. POT1 mutations cause telomere dysfunction in chronic lymphocytic leukemia.
Ramsay AJ; Quesada V; Foronda M; Conde L; Martínez-Trillos A; Villamor N; Rodríguez D; Kwarciak A; Garabaya C; Gallardo M; López-Guerra M; López-Guillermo A; Puente XS; Blasco MA; Campo E; López-Otín C
Nat Genet; 2013 May; 45(5):526-30. PubMed ID: 23502782
[TBL] [Abstract][Full Text] [Related]
30. Pot1b -/- tumors activate G-quadruplex-induced DNA damage to promote telomere hyper-elongation.
Takasugi T; Gu P; Liang F; Staco I; Chang S
Nucleic Acids Res; 2023 Sep; 51(17):9227-9247. PubMed ID: 37560909
[TBL] [Abstract][Full Text] [Related]
31. NEK6-mediated phosphorylation of human TPP1 regulates telomere length through telomerase recruitment.
Hirai Y; Tamura M; Otani J; Ishikawa F
Genes Cells; 2016 Aug; 21(8):874-89. PubMed ID: 27396482
[TBL] [Abstract][Full Text] [Related]
32. A
Abu Shtaya A; Kedar I; Bazak L; Basel-Salmon L; Barhom SF; Naftali M; Eskin-Schwartz M; Birk OS; Polager-Modan S; Keidar N; Reznick Levi G; Levi Z; Yablonski-Peretz T; Mahamid A; Segol O; Matar R; Bareli Y; Azoulay N; Goldberg Y
Genes (Basel); 2024 Mar; 15(3):. PubMed ID: 38540414
[TBL] [Abstract][Full Text] [Related]
33. The short and long telomere syndromes: paired paradigms for molecular medicine.
Stanley SE; Armanios M
Curr Opin Genet Dev; 2015 Aug; 33():1-9. PubMed ID: 26232116
[TBL] [Abstract][Full Text] [Related]
34. Expression of Shelterin component POT1 is associated with decreased telomere length and immunity condition in humans with severe aplastic anemia.
Wang T; Mei SC; Fu R; Wang HQ; Shao ZH
J Immunol Res; 2014; 2014():439530. PubMed ID: 24892036
[TBL] [Abstract][Full Text] [Related]
35. Adaptive and Maladaptive Clonal Hematopoiesis in Telomere Biology Disorders.
Lasho T; Patnaik MM
Curr Hematol Malig Rep; 2024 Feb; 19(1):35-44. PubMed ID: 38095828
[TBL] [Abstract][Full Text] [Related]
36. Lack of mutations of the telomerase RNA component in familial papillary thyroid cancer with short telomeres.
Cantara S; Capuano S; Capezzone M; Benigni M; Pisu M; Marchisotta S; Pacini F
Thyroid; 2012 Apr; 22(4):363-8. PubMed ID: 22304389
[TBL] [Abstract][Full Text] [Related]
37. Structural insights into POT1-TPP1 interaction and POT1 C-terminal mutations in human cancer.
Chen C; Gu P; Wu J; Chen X; Niu S; Sun H; Wu L; Li N; Peng J; Shi S; Fan C; Huang M; Wong CC; Gong Q; Kumar-Sinha C; Zhang R; Pusztai L; Rai R; Chang S; Lei M
Nat Commun; 2017 Apr; 8():14929. PubMed ID: 28393832
[TBL] [Abstract][Full Text] [Related]
38. Mutations in POT1 predispose to familial cutaneous malignant melanoma.
Trigueros-Motos L
Clin Genet; 2014 Sep; 86(3):217-8. PubMed ID: 24784786
[No Abstract] [Full Text] [Related]
39. Identification of a Cancer-Predisposing Germline
Jajosky AN; Mitchell AL; Akgul M; Shetty S; Yoest JM; Gerson SL; Sadri N; Oduro KA
Genes (Basel); 2022 Mar; 13(4):. PubMed ID: 35456397
[TBL] [Abstract][Full Text] [Related]
40. Telomere Length and Clonal Hematopoiesis.
Vassiliou G
N Engl J Med; 2023 Jun; 388(26):2481-2484. PubMed ID: 37140164
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
